ArticleCancer immunology, immunotherapy : CII2021

COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.

Kyle Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.